# A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

> **NCT01458288** · PHASE2 · COMPLETED · sponsor: **GPCR Therapeutics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Multiple Myeloma
- Non-hodgkin's Lymphoma
- Hodgkin's Disease

## Interventions

- **DRUG:** TG-0054

## Key facts

- **NCT ID:** NCT01458288
- **Lead sponsor:** GPCR Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458288, "A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01458288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*